Guide · dosing

GLP-1 microdosing, and what the trials do not say about it

A fast-growing tier of this market sells a fraction of the studied dose at a fraction of the price. Here is who offers it, what it costs, and the one thing every microdose page leaves out.

Updated 2026-08-157 sources

What is being sold

Microdosing means taking a fraction of the dose the medication was studied at. It has become a distinct product tier: cheaper, gentler on side effects by design, and marketed as an easier way in. Every microdose offering we verified is compounded rather than brand-name, because the approved products are not sold at those strengths.

Verified microdose offerings
Provider	Price	Molecules	Notable terms
AgelessRx	from $99/mo	Semaglutide, tirzepatide	No separate membership; free shipping; cancel before next shipment
Noom	$179/mo + tax	Semaglutide, tirzepatide	$49 starter; medication bundled into the price; FSA/HSA eligible
24hrDoc	$129/mo	Not stated	$110 first month; does not say whether compounded
Lemonaid	$199/mo	Semaglutide, tirzepatide	Plus the $49/mo membership, so $248 all-in

AgelessRx is the cheapest verified route at $99/month with no membership on top. Noom is the only one to bundle medication and programme into a single price.

The thing the microdose pages do not tell you

What the sellers do disclose

Noom: “Compounded semaglutide available through Noom-GLP1ᴿˣ is produced in an FDA-registered facility but has not been reviewed by the FDA for safety, efficacy, or quality.” The distinction between a registered facility and a reviewed medicine is the whole point, and Noom is one of the few to draw it.
AgelessRx: “Compounded at a US-licensed pharmacy,” and “compounded GLP-1s have not been evaluated by the FDA.”
Neither publishes lab requirements. Neither states what fraction of a standard dose their microdose actually is.

The honest case for it

There is one. Gastrointestinal side effects in this class are concentrated in the escalation phase, and they are the most common reason people stop. A lower starting dose is a real clinical strategy, and holding a dose rather than pushing through is standard practice.

The difference is that a supervised slow titration is aiming at a therapeutic dose eventually. A microdose subscription is not necessarily aiming anywhere — and if it stays at a fraction of the studied dose indefinitely, you are paying monthly for something whose effect size nobody has published.

Questions to ask before starting a microdose plan

What fraction of the standard dose is this, in milligrams?
Is there a titration plan toward a therapeutic dose, or is the microdose the destination?
What evidence is there for the effect size at this dose specifically?
What is the concentration of the vial, and is my dose expressed in units or millilitres?
What is the total monthly cost including any membership, and when does it renew?

What compounded means, and where the rules are heading

Compounded GLP-1s are not FDA-approved products. Several of the services selling them say so on their own sales pages: Alloy states that “unlike FDA-approved drugs, compounded medications are not reviewed by the FDA for safety, effectiveness, or quality,” and Noom draws the sharper distinction — its product is “produced in an FDA-registered facility but has not been reviewed by the FDA for safety, efficacy, or quality.” A registered facility is not a reviewed medicine.

This tier is now under active enforcement. FDA announced 30 warning letters to telehealth companies in March 2026 and a further 25 in June, over false or misleading marketing of compounded GLP-1 products — including claiming or implying FDA approval, and describing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed,” which is an authorisation the agency does not grant. Five providers reviewed on this site are named recipients; their reviews say so at the top.

The larger development is structural, and it is worth quoting exactly. In a notice published on 1 May 2026 (91 FR 23431, Docket FDA-2018-N-3240), FDA said it “proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide.” That list is the set of substances for which FDA has found “a clinical need for outsourcing facilities to use in compounding”. Leaving all three off it would remove the legal basis for 503B outsourcing facilities to compound them in bulk — which is most of the cheap tier on this site.

It is a proposal, not a rule, and it is not settled. FDA extended the comment period on 26 June 2026, moving the deadline to 30 July. Nothing has been finalised as of this update. But anyone signing a twelve-month prepaid compounded plan should understand that the supply may not be lawful for the length of the plan, and should ask the provider what happens to the balance if it is not.

We could not retrieve fda.gov directly during this research, so the warning-letter counts are cited from the search index. The Federal Register notices above are quoted from the Federal Register’s own API.

Questions

Does microdosing work?

We cannot tell you, and neither can the providers selling it — none publishes an effect size at microdose levels. The trial results quoted across this site were produced at full therapeutic doses. Treat microdosing as a tolerability strategy rather than as a cheaper route to the published outcomes.

What is the cheapest microdose option?

AgelessRx at $99/month for semaglutide, with no separate membership. Noom bundles medication and programme at $179/month and is the only one to confirm HSA and FSA eligibility.

Is microdosing safer?

Lower doses generally mean fewer gastrointestinal side effects, which is the main argument for it. But the compounded supply adds its own risk — vial-and-syringe dosing puts the arithmetic on you, and FDA has published an alert about dosing errors with compounded semaglutide.

Sources

Everything on this page traces to one of the links below, retrieved on the date shown. Prices and programme terms in this market change without notice — confirm against the provider before you buy.

01Noom — GLP-1 Microdose (pricing, compounding disclosure, HSA/FSA)retrieved 2026-08-15
02AgelessRx — Microdosing GLP-1 (pricing, compounding disclosure, cancellation)retrieved 2026-08-15
03Lemonaid Health — weight loss pricing and membershipretrieved 2026-08-14
04FDA — “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (cited from search index; fda.gov refused direct retrieval)retrieved 2026-08-14
05FDA — “FDA alerts health care providers, compounders and patients of dosing errors” (cited from search index)retrieved 2026-08-14
06FDA — “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1 Drugs”, 3 March 2026 (cited from the search index)retrieved 2026-08-16
07FDA — “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List”, April 2026 (cited from the search index)retrieved 2026-08-16